MetaCap

Altimmune Inc. (ALT)

NASDAQ: ALTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.33-0.08 (-5.67%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ALT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$258.80M
EPS (TTM)
-$0.71
52-week range
1.32 – 6.44
Day range
1.32 – 1.46
Volume / Avg
4.02M / 3.91M
Beta
—

52-week range

$1.32$6.44

ALT stock today

On Nov 20, ALT ended the session at $1.33, shedding $0.08 (5.67%), versus the S&P 500's 3.70% decline. Shares are 79.3% below their 52-week high of $6.44, set on Jan 23, 2026 and 0.8% above the 52-week low of $1.32, near the bottom of the past year's range. ALT is down 63.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 72.3%.

Altimmune has posted a net loss over the last twelve months (EPS of -$0.71), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Altimmune

Company profile

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Jerome Benedict Durso
Headquarters
Gaithersburg, MD
Employees
57

Financial highlights

Full financials

In fiscal 2025, Altimmune generated $41,000 in revenue, up 105.0% from fiscal 2024. Altimmune reported a net loss of $88.1 million, compared with a loss of $95.1 million a year earlier. Operating margin was -230461.0%.

Altimmune annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$41.00K$20.00K$426.00K$-68.00K$4.41M
Growth+105.00%-95.31%+726.47%-101.54%-46.12%
Net income$-88.09M$-95.06M$-88.45M$-84.71M$-97.09M
EPS (diluted)$-1.00$-1.34$-1.66$-1.81$-2.35

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$16.33+1127.82%

  • Strong buy 2
  • Buy 7
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $11.00High $26.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.15 vs $-0.14
Surprise
-7.14%

ALT news

All ALT news

Altimmune peers

Health Care sector
ALT peer companies
CompanyPrice% ChgMarket capCompare
PRLDPrelude Therapeutics Incorporated3.23-0.77%$258.63Mvs ALT
EBSEmergent BioSolutions Inc.5.05-1.94%$259.65Mvs ALT
VCREVicore Pharma Holding AB ADR9.41-5.09%$264.89Mvs ALT
QTTBQ32 Bio Inc.8.34-1.65%$249.57Mvs ALT
TTRXTurn Therapeutics Inc.8.10-6.31%$247.49Mvs ALT
GALTGalectin Therapeutics Inc.2.69-4.27%$271.35Mvs ALT
LFCRLifecore Biomedical Inc.6.39+0.31%$242.22Mvs ALT
RLMDRelmada Therapeutics Inc.2.62-15.76%$279.54Mvs ALT

Indexes, lists and sector

Altimmune stock FAQ

What is Altimmune's stock price today?

ALT last traded at $1.33 as of Nov 20, 4:00 PM EST, down 5.67% on the day. Prices are delayed at least 15 minutes.

Does Altimmune pay a dividend?

No. Altimmune does not currently pay a regular cash dividend.

Who is Altimmune's CEO?

Mr. Jerome Benedict Durso is the chief executive officer of Altimmune Inc., which has about 57 employees.

Has ALT ever split its stock?

Yes. The most recent ALT stock split was a 1-for-30 split on Sep 14, 2018.

What is the ALT 52-week high?

The 52-week high for ALT is $6.44 and the 52-week low is $1.32. The stock is currently 79.3% below its high.

Compare ALT